Drugs / anti-KRAS G12D mTCR-transduced PBL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03745326 | May 2019 → Aug 2022 | colon carcinoma, gastric cancer, malignant pancreatic neoplasm, rectal cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-KRAS G12D mTCR-transduced PBL | “Determine if anti-KRAS G12D mTCR-transduced PBL can mediate the regression of tumors harboring the rat sarcoma (RAS) G12D mutation.” NCT03745326 ↗ |
| Action | Deplete | “mTCR transduced T-cells lyse target cells” NCT03745326 ↗ |
| Route | Intravenous | “Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes” NCT03745326 ↗ |
| Target | KRAS | “anti-KRAS G12D mTCR-transduced PBL” NCT03745326 ↗ |